Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
127 GBX | -1.17% | -7.64% | -30.41% |
Sales 2023 * | 5.01M 6.24M | Sales 2024 * | 7.58M 9.44M | Capitalization | 39.36M 48.98M |
---|---|---|---|---|---|
Net income 2023 * | -6M -7.47M | Net income 2024 * | -6M -7.47M | EV / Sales 2023 * | 6.62 x |
Net cash position 2023 * | 6.17M 7.68M | Net cash position 2024 * | 2.08M 2.59M | EV / Sales 2024 * | 4.92 x |
P/E ratio 2023 * |
-5.35
x | P/E ratio 2024 * |
-5.98
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 day | -1.17% | ||
1 week | -7.64% | ||
Current month | -9.29% | ||
1 month | -13.90% | ||
3 months | -24.63% | ||
6 months | -33.16% | ||
Current year | -30.41% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | - |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 18-12-31 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 07-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | - |
Christine Soden
BRD | Director/Board Member | 66 | 21-04-30 |
Andrew Richards
CHM | Chairman | 64 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 127 | -1.17% | 2 502 |
24-04-18 | 128.5 | 0.00% | 0 |
24-04-17 | 128.5 | -1.15% | 247,000 |
24-04-16 | 130 | -1.89% | 16,323 |
24-04-15 | 132.5 | -3.64% | 17,907 |
Delayed Quote London S.E., April 19, 2024 at 04:24 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.41% | 49.05M | |
-1.82% | 41.35B | |
+43.06% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- AREC Stock